Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Abrocitinib for Patients with Moderate to Severe Chronic Hand Eczema Unresponsive to Corticosteroids

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying chronic hand eczema, a skin condition that causes redness, itching, and sometimes blisters on the hands. The trial will evaluate a treatment called abrocitinib, which is a type of medication known as a Janus kinase (JAK)1 inhibitor. This medication is being tested to see if it can help people with moderate to severe chronic hand eczema that has not improved with corticosteroid therapy, a common treatment for this condition.

The purpose of the study is to assess the effectiveness, safety, and tolerability of abrocitinib in treating chronic hand eczema. Participants in the study will be randomly assigned to receive either the medication or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of 32 weeks, during which participants will take the medication or placebo orally in the form of film-coated tablets. Throughout the study, participants will have regular check-ups to monitor their condition and any changes in their symptoms.

This trial aims to provide valuable information on whether abrocitinib can be an effective treatment option for those suffering from chronic hand eczema. By participating, individuals will contribute to research that could lead to better management of this challenging skin condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on criteria such as age, history of hand eczema, and current condition severity.

    Participants must be adults aged 18 or older with moderate to severe chronic hand eczema that has not responded to corticosteroid therapy.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to evaluate the severity of hand eczema using a hand Physician's Global Assessment (PGA) score.

    The assessment ensures the condition is moderate to severe, with a score of 3 or 4.

  3. Step 3

    Medication administration

    Participants receive either abrocitinib or a placebo in the form of 100 mg film-coated tablets.

    The medication is taken orally, following the prescribed dosage and schedule.

  4. Step 4

    Ongoing evaluations

    Regular evaluations occur at Weeks 2, 4, 12, and 16 to monitor changes in the condition.

    These evaluations include measuring the percent change from baseline in various scores such as hand mTLSS, HESCI, and others.

  5. Step 5

    Final assessment

    At Week 16, a final assessment is conducted to determine the overall efficacy of the treatment.

    The primary endpoint is the percent change from baseline in hand mTLSS.

  6. Step 6

    Safety monitoring

    Throughout the study, safety is monitored through vital signs and laboratory tests.

    Any adverse events or side effects are recorded and evaluated.

Who can join the trial?

5 criteria

  • The patient must be an adult, which means they are 18 years of age or older.
  • The patient should have had **moderate to severe chronic hand eczema** for at least 6 months before the start of the study. **Chronic hand eczema** is a long-lasting skin condition that affects the hands.
  • The patient must have **refractory hand eczema**, which means their hand eczema does not improve with standard treatments.
  • The patient should have **moderate to severe chronic hand eczema** at the time of screening and on the first day of the study. This is determined by a specific assessment called a **hand PGA** (Physician's Global Assessment) with a score of 3 or 4.
  • Women who can have children, or their male partners, must use birth control during the study and for at least 4 weeks after the last dose of the study medication. This should follow local rules and availability of birth control methods for people in clinical trials.

Who cannot join the trial?

3 criteria

  • Patients who do not have moderate to severe chronic hand eczema cannot participate. This means if your hand eczema is mild or not chronic, you are not eligible.
  • Patients who are not within the specified age range cannot participate. The age range is not specified here, but it usually means you need to be within a certain age group.
  • Patients who are part of a vulnerable population may not be eligible. A vulnerable population can include groups like pregnant women, children, or people with certain disabilities.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Abrocitinib is a medication being studied for its effectiveness in treating moderate to severe chronic hand eczema, especially in patients who have not responded well to corticosteroid treatments. It works by targeting specific pathways in the immune system that are involved in inflammation, potentially reducing the symptoms of eczema such as redness, itching, and swelling.

What is already known about the treatment

Abrocitinib – Abrocitinib is administered orally in tablet form. It is currently being studied in clinical trials for its effectiveness in treating moderate to severe chronic hand eczema, particularly in cases where corticosteroid therapy has not been successful. The medication works by inhibiting Janus kinase (JAK) enzymes, which play a role in the inflammatory process, thereby reducing inflammation and symptoms associated with eczema. Abrocitinib is classified as a JAK inhibitor, a type of medication that targets specific pathways involved in immune response and inflammation.

Investigated diseases

Chronic Hand Eczema – Chronic hand eczema is a skin condition characterized by inflammation, redness, and itching on the hands. It often results in dry, cracked, and thickened skin, which can be painful and uncomfortable. The condition can be triggered by irritants, allergens, or genetic factors, and it tends to persist over time. Symptoms may fluctuate, with periods of worsening and improvement. Chronic hand eczema can significantly impact daily activities due to discomfort and the visible nature of the condition. It is important to manage triggers and maintain skin care to help control symptoms.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-504539-42-00Protocol codeINNO-6052Estimated enrolment84 patientsSponsorInnovaderm Research Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.